Anika Therapeutics, Inc. (ANIK) Gross margin 2016–2025
Anika Therapeutics, Inc. (ANIK) gross margin by fiscal year — reported gross profit divided by reported revenue.
56.6%FY2025 · since FY2016: 76.8% → 56.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 56.6% | -6.8 pp |
| FY2024 | 63.4% | -4.9 pp |
| FY2023 | 68.3% | +4.0 pp |
| FY2022 | 64.3% | +8.2 pp |
| FY2021 | 56.1% | +3.2 pp |
| FY2020 | 52.9% | -22.0 pp |
| FY2019 | 74.9% | +4.6 pp |
| FY2018 | 70.4% | -5.5 pp |
| FY2017 | 75.9% | -0.9 pp |
| FY2016 | 76.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIK financial trends
ANIK RevenueANIK Net incomeANIK Net marginANIK Gross profitANIK Operating incomeANIK Operating marginANIK Operating cash flowANIK Free cash flowANIK Capital expendituresANIK Return on equityANIK Stock buybacksANIK Dividends paidANIK Total assetsANIK Total liabilitiesANIK Shareholders’ equityANIK overview →